Fractionated stereotactic radiotherapy (fSRT) for symptomatic WHO grade 1 cavernous sinus meningiomas: long-term local control, clinical response, and toxicity outcomes - Takeaways - MDSpire

Fractionated stereotactic radiotherapy (fSRT) for symptomatic WHO grade 1 cavernous sinus meningiomas: long-term local control, clinical response, and toxicity outcomes

  • By

  • Ryan Shah

  • Shray Jain

  • Nilanjan Haldar

  • Lauren A. Holt

  • Robert L. Walker

  • Christopher J. Farrell

  • Debanjan Haldar

  • James J. Evans

  • Gregory S. Alexander

  • Wenyin Shi

  • June 30, 2026

  • 0 min

Share

  • 1

    Meningiomas are the most common primary intracranial neoplasm in adults, with a higher incidence in patients over 65 years old.

  • 2

    Over 80% of meningiomas are benign, low-grade tumors that can cause significant morbidity through compression of critical brain structures.

  • 3

    Fractionated stereotactic radiotherapy (fSRT) delivers 50–54 Gy over 25–30 fractions and offers reduced risks compared to stereotactic radiosurgery (SRS).

  • 4

    Long-term local control rates with fSRT for cavernous sinus meningiomas exceed 85% at 5 and 10 years, with a superior complication profile compared to SRS.

  • 5

    The study aims to report long-term outcomes, including local control, symptom response, and treatment-related toxicity for patients treated with fSRT.

Original Source(s)

Fractionated stereotactic radiotherapy (fSRT) for symptomatic WHO grade 1 cavernous sinus meningiomas: long-term local control, clinical response, and toxicity outcomes

  • by Ryan Shah, Shray Jain, Nilanjan Haldar, Lauren A. Holt, Robert L. Walker, Christopher J. Farrell, Debanjan Haldar, James J. Evans, Gregory S. Alexander, Wenyin Shi

  • June 30, 2026

Related Content

Real-world evidence on data quality in precision oncology platforms: insights from the Molecular Twin Research Umbrella protocol

Unmasking biomarkers in small cell lung cancer: implication for precision oncology

Endoscopic and histopathological phenotypes of early gastric neoplasia: toward an integrative host-response framework